Early screening of your heart valves
1 in 9
over 65s have significant valvular heart disease. This is nearly 2 million people in the UK and will grow rapidly due to the ageing population.
of patients are undiagnosed and will progress to late stage where the prognosis is worse than advanced stage cancer.
additional cost to the NHS per year because of treating patients at a later, symptomatic stage.
The current detection pathway for VHD is inadequate
2. GP stethoscope exam
Our solution: a novel medical device to enable community screening of valve disease
Novel acoustic hardware
Our models are trained and evaluated on our proprietary datasets – thousands of recordings from actual NHS patients with valvular heart disease.
We are a spin-out from the University of Cambridge Acoustics Lab. We are a team of engineers, machine learning experts and experienced clinicians who are all passionate about transforming patient lives by improving early detection of disease across the world.
Dr. Andrew McDonald
CEO & Co-Founder
Prof. Anurag Agarwal
CSO & Co-Founder
Prof. Rick Steeds
Chief Medical Advisor
Prof. Steve Young CBE FRS FREng
Prof. Mark Gales
Professor of Information Engineering,
University of Cambridge.
Jamal Butt FRPharmS
CEO, MedAdvisor UK. Non-Exec Director, Croydon NHS Trust. Former Head of Pharmacy, Boots UK.
Dr. Katja Kostelnik
Dr. Girish Sabnis
King Edwards Hospital Mumbai.
Prof. Bernard Prendergast
Consultant Cardiologist, St Thomas’ Hospital. Chair of Cardiology, Cleveland Clinical London.